SHENZHEN, China, June 30, 2026 /PRNewswire/ -- Tencent Music Entertainment Group ("TME," or the "Company") (NYSE: TME and HKEX: 1698), the leading online music and audio entertainment platform in China, today announced that its annual general meeting (the "AGM") was held in Hong Kong on June 30, 2026 and all the proposed resolutions set out in the notice of the AGM dated May 20, 2026 were duly passed at the AGM.

About Tencent Music Entertainment

Tencent Music Entertainment Group (NYSE: TME and HKEX: 1698) is the leading online music and audio entertainment platform in China, operating the country's highly popular and innovative music apps: QQ Music, Kugou Music, Kuwo Music and WeSing. TME's mission is to create endless possibilities with music and technology. TME's platform comprises online music, online audio, online karaoke, music-centric live streaming and online concert services, enabling music fans to discover, listen, sing, watch, perform and socialize around music. For more information, please visit ir.tencentmusic.com.

Investor Relations Contact
Tencent Music Entertainment Group
[email protected]
+86 (755) 8601-3388 ext. 885034

Seven creators from five continents shared stories of movement while more than 3,000 people joined a community run in Hong Kong

SHENZHEN, China, June 30, 2026 /PRNewswire/ -- TCL, a leading global technology company and a Worldwide Olympic and Paralympic Partner, has concluded its global campaign for Olympic Day 2026, supporting the International Olympic Committee (IOC)'s "Let's Move" initiative celebrating the joy of movement and sport.

The campaign began with seven creators sharing their interpretations of the Olympic spirit through film, family activities, fashion, culture and movement. Their stories were brought together in a montage filmed around the world to spark cross-platform conversations under the brand slogan "Inspire Greatness" and the social media hashtag #JointheGreatness. The celebration then moved into the community with the "Run with Hong Kong Athletes" event on June 28.

"We've seen that the magic of the Olympic Games isn't just in the stadiums; it's in living rooms, streets and communities across the globe. We at TCL are proud to provide new ways for people around the world to connect with this spirit and inspire their own greatness," said Wei Xue, Vice President and ESG Director of TCL Technology and Chairman of the TCL Charity Foundation.

Seven Creators Share One Global Story

The seven creators from five continents, reaching a combined social following of more than 21 million people, explored how the concept of Inspire Greatness and the Olympic spirit take on different cultural meanings worldwide, and how TCL's technology can bring them to life in ways that resonate across cultures.

In the United States, cinematic storytelling paid tribute to the history of film, moving from black-and-white to vivid color. In France, families turned their living rooms into spaces for friendly competition, using games and challenges inspired by the sporting action on screen. In New Zealand, movement drew on Māori heritage and a close connection to the land, while in South Africa, creators brought together sport, fashion and the ambitions of a new generation. In Japan, parkour, gaming-inspired visuals and augmented reality connected movement through the streets of Tokyo, reflecting the energy and determination seen on the sporting stage.

The montage film created one continuous global celebration through seamless transitions between people, places and screens, inviting viewers to share their own experiences under the hashtag #JointheGreatness – whether they tried out a new sport, overcame an everyday challenge, or simply chose to move. By celebrating participation rather than sporting achievement alone, the campaign reflected a central idea behind Olympic Day: everyone can be part of the movement.

Over 3,000 People Join Hong Kong Community Run

The campaign continued in Hong Kong on June 28, when more than 3,000 people took part in the "Run with Hong Kong Athletes" event.

Organized in collaboration with the IOC and the Sports Federation and Olympic Committee of Hong Kong, China, and sponsored by TCL, the event brought the "Let's Move" invitation directly into the local community. Runners of different ages and backgrounds gathered to enjoy sport and experience the Olympic spirit outside the competition arena, celebrating Olympic Day alongside local athletes. TCL hosted a booth on site, helping to provide entertainment for attendees, while more than 30 TCL employees embodied the spirit of "Inspire Greatness" by joining the run.

Following the stories of movement shared across five continents, the Hong Kong runners united to write their own collective chapter, bridging the campaign's message with the physical world.

Bringing the Arena Closer

Display technology played an important role throughout the campaign, helping creators connect sporting moments on screen with real-world movement, and bringing the inspiration of the Olympic Games into everyday life.

TCL SQD-Mini LED TVs combine an expansive picture with advanced color reproduction and fine visual detail. By reproducing the expressions, movement and emotion that define decisive sporting moments, the TVs become an extension of the arena, bringing audiences closer to the action.

The campaign also showcased TCL RayNeo AR glasses, pointing to more personal and immersive ways to enjoy sports entertainment. By placing digital content within the wearer's natural field of view, the glasses offer a large-format viewing experience that can be enjoyed almost anywhere.

A Year-Round Olympic Journey

The Olympic Day campaign continues a year of activities through which TCL has connected technology, sport and local communities.

Ahead of the Olympic and Paralympic Winter Games Milano Cortina 2026, TCL created its "Wishes for Greatness" winter wonderland in Milan's Piazza del Duomo. Additionally, the company opened TCL Edelweiss Land in Milan, where visitors experienced its latest display technology, augmented reality products and smart home appliances. Team TCL built on the same "Inspire Greatness" vision, highlighting that greatness takes many forms by supporting athletes pursuing success at the highest level, while encouraging people everywhere to follow their own ambitions.

From Milan's festive celebrations to the streets of Hong Kong, TCL's role as a Worldwide Olympic and Paralympic Partner extends beyond the events themselves. It represents a long-term commitment to using technology to bring people closer to sport, to one another and to the moments that inspire greatness in everyday life.

About TCL

Founded in 1981, TCL—short for "The Creative Life"—is dedicated to empowering smarter, healthier lifestyles through next-generation experiences. Operating through two independent entities, TCL Industries and TCL Technology, TCL delivers innovative solutions spanning TVs, smartphones, audio products, smart home devices, display technologies, and clean energy. 

Today, with 47 R&D centers and 41 manufacturing bases globally, TCL operates in over 160 countries and regions, reinforcing its position as a globally competitive smart technology brand. To further inspire greatness, TCL has become an official Worldwide Olympic and Paralympic Partner in the Home Audiovisual Equipment and Home Appliances category. 

https://www.tcl.com/global/en 

BEIJING, June 30, 2026 /PRNewswire/ -- New Oriental Education and Technology Group Inc. (the "Company" or "New Oriental") (NYSE: EDU/ 9901.SEHK), a provider of private educational services in China, today announced that it will report its financial results for the fourth quarter ended May 31, 2026, before the U.S. market opens on July 29, 2026. New Oriental's management will host an earnings conference call at 8 AM on July 29, 2026, U.S. Eastern Time (8 PM on July 29, 2026, Beijing/Hong Kong Time). Participants can join the conference using the below options:

Dialling-in to the conference call:

Please register in advance of the conference, using the link provided below. Upon registering, you will be provided with participant dial-in numbers, and unique personal PIN.

Conference call registration link:

https://register-conf.media-server.com/register/BIffe9352b170044a4b248e41d134aed08. It will automatically direct you to the registration page of "New Oriental FY2026 Q4 Earnings Conference Call" where you may fill in your details for RSVP.

In the 10 minutes prior to the call start time, you may use the conference access information (including dial in number(s) and personal PIN) provided in the confirmation email received at the point of registering.

Joining the conference call via a live webcast:

Additionally, a live and archived webcast of the conference call will be available at http://investor.neworiental.org.

Listening to the conference call replay:

A replay of the conference call may be accessed via the webcast on-demand by registering at https://edge.media-server.com/mmc/p/pdsxxtdn first. The replay will be available until July 29, 2027.

About New Oriental

New Oriental is a provider of private educational services in China offering a wide range of educational programs, services and products to a varied student population throughout China. New Oriental's program, service and product offerings mainly consist of educational services and test preparation courses, private label products and livestreaming e-commerce, overseas study consulting services, and educational materials and distribution. New Oriental is listed on NYSE (NYSE: EDU) and SEHK (9901.SEHK), respectively. New Oriental's ADSs, each of which represents ten common shares, are listed and traded on the NYSE. The Hong Kong-listed shares are fully fungible with the ADSs listed on NYSE.

For more information about New Oriental, please visit http://www.neworiental.org/english/.

Contacts

WUXI, China, June 30, 2026 /PRNewswire/ -- WuXi Biologics (2269.HK), a leading global Contract Research, Development, and Manufacturing Organization (CRDMO), announced that two of its manufacturing facilities in Wuxi — Drug Substance Facility 2 (MFG2) and Drug Product Facility 1 (DP1) — together with its Drug Product Packaging Center (DPPC), have received GMP certification from Brazil's Agência Nacional de Vigilância Sanitária (ANVISA). The certification positions WuXi Biologics to provide end‑to‑end commercial manufacturing services — covering both drug substance and drug product — for an anti-PD-L1 monoclonal antibody used in cancer immunotherapy.

Based on the five-day inspection, MFG2, DP1 and DPPC successfully passed ANVISA's assessment with zero findings. The inspection results demonstrate WuXi Biologics' robust quality management system, mature GMP execution, and efficient cross-functional collaboration, while verifying the company's comprehensive capabilities to support client needs for global commercial manufacturing and supply.

Within WuXi Biologics' global GMP manufacturing network, MFG2, DP1 and DPPC collectively provide integrated, end-to-end capabilities spanning large-scale biologics drug substance manufacturing, clinical and commercial drug product fill-finish, and customized packaging, meeting regulatory requirements across major markets worldwide. Together, these capabilities enable seamless manufacturing and reliable commercial supply for innovative biologic therapies.

Dr. Chris Chen, CEO of WuXi Biologics, commented, "Receiving ANVISA GMP certification reflects WuXi Biologics' continued commitment to global quality and compliance standards, and further validates our international standards across facilities, quality systems, and GMP execution. Looking ahead, we will continue to leverage our world-class quality system and end-to-end manufacturing capabilities to enable clients' global commercialization strategies, including entry into Latin America. By accelerating the delivery of high-quality, affordable biologics, we are helping to broaden access to innovative biologics for patients around the world."

WuXi Biologics has consistently demonstrated a proven track record of adherence to the industry's rigorous quality standards. As of the end of 2025, it has successfully passed 46 regulatory inspections, including 22 conducted by the FDA and EMA, and secured 136 facility license approvals. The company also holds an industry-leading record, achieving a 100% pass rate for FDA Pre-License Inspection (PLI). In addition, WuXi Biologics has passed more than 1,800 GMP quality audits by global clients, including over 230 audits by EU Qualified Persons. Currently, the company operates 15 GMP-certified drug substance and drug product facilities within its global network. Its world-class quality and compliance capabilities underpin long-standing trust from clients worldwide.

About WuXi Biologics

WuXi Biologics (stock code: 2269.HK) is a leading global Contract Research, Development and Manufacturing Organization (CRDMO) offering end-to-end solutions that enable partners to discover, develop and manufacture biologics — from concept to commercialization — for the benefit of patients worldwide*.

With over 13,000 employees in China, the United States, Ireland, Germany, and Singapore — including experts and scientists in biologics R&D and manufacturing, technology innovation, and operational excellence — WuXi Biologics leverages its technologies and expertise to deliver efficient, cost-effective, and scalable biologics solutions tailored to meet clients' needs. By embedding digital capability and infrastructure across the full biopharmaceutical value chain, the company turns data, computation, and prediction into transparent client experience, faster development, intelligent operations, and more efficient manufacturing. As of April 30, 2026, WuXi Biologics is supporting 982 integrated client projects, including 78 in Phase III and 25 in commercial manufacturing, with complex modalities representing more than half of the entire project portfolio.

WuXi Biologics regards sustainability as the cornerstone of long-term business growth. The company continuously drives technology innovations to offer advanced end-to-end Green CRDMO solutions for its global partners while demonstrating exemplary Environmental, Social and Governance (ESG) practices. Committed to creating shared value, it collaborates with all stakeholders to foster positive social and environmental impacts, and promote responsible practices that empower the entire value chain.

For more information about WuXi Biologics, please visit: www.wuxibiologics.com. 

*The winner of the "2026 Biologics CDMO of the Year" (Large CDMOs) (Life Science Connect / Outsourced Pharma)

*The winner of the "2026 Best Contract Development & Manufacturing Organization Award" (ABEA)

Contacts
Business
[email protected] 

Media
[email protected]

SAN FRANCISCO and SUZHOU, China, June 30, 2026 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures, and commercializes high-quality medicines for the treatment of oncology, autoimmune, cardiovascular and metabolic, ophthalmology and other major disease areas, and Eli Lilly and Company (NYSE: LLY) today jointly announced that they have entered into a distribution and promotion agreement regarding Lilly's CDK4 & 6 inhibitor Verzenios^® (abemaciclib) in mainland China:

• Innovent will be responsible for the importation, marketing, distribution and promotion of Verzenios^® (abemaciclib) in mainland China;
• Lilly will continue to be responsible for manufacturing, supply, and development for the product.

Verzenios^® (abemaciclib), developed by Lilly, is a CDK4 & 6 inhibitor that has been approved in China for multiple indications, including:

(1) Early Breast Cancer: in combination with endocrine therapy (tamoxifen or an aromatase inhibitor) for the adjuvant treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, node-positive early breast cancer at high risk of recurrence.
(2) Locally Advanced or Metastatic Breast Cancer:
a) For the treatment of hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative locally advanced or metastatic breast cancer:

• In combination with an aromatase inhibitor as initial endocrine-based therapy in postmenopausal women.
• In combination with fulvestrant for patients who have experienced disease progression following prior endocrine therapy.

b) In combination with imlunestrant: for the treatment of adult patients with estrogen receptor (ER)-positive, HER2-negative, ESR1-mutated locally advanced or metastatic breast cancer who have previously received endocrine therapy.

The product was included in the National Reimbursement Drug List (NRDL) Class B in 2021, becoming the first CDK4 & 6 inhibitor covered by national reimbursement in China. In 2025, it successfully renewed its NRDL listing, achieving full coverage across both early and advanced breast cancer indications.

Under the agreement, Innovent will hold sole commercialization rights for Verzenios^® (abemaciclib) in mainland China, while Lilly, as the Marketing Authorization Holder (MAH), will continue to be responsible for manufacturing, supply, and ongoing product development. This collaboration combines Innovent's experienced oncology commercialization team and extensive market reach in China with Lilly's expertise in innovative medicine development and lifecycle management, further enhancing access to this important therapy and benefiting more breast cancer patients across the country.

Dr. Michael Yu, Founder, Chairman of the Board and CEO of Innovent, stated: "We are delighted to further deepen our strategic partnership with Lilly through this eighth collaboration, bringing the number of our partnered, on-market products in China to seven. This also marks the 19^th product in Innovent's portfolio. Enhancing patient access to high-quality, innovative medicines has always been at the core of Innovent's mission. Leveraging our established commercial infrastructure and strong market presence in China, we remain focused on addressing critical unmet needs in major oncology indications. Breast cancer, one of the most prevalent and life–threatening malignancies among women, is a strategic priority within Innovent's oncology portfolio. Through this commercial collaboration with Lilly on Verzenios^® (abemaciclib) – backed by its robust clinical efficacy, comprehensive labeled indications and national reimbursement coverage – we are expanding our presence in this area, laying a solid foundation for our pipeline development and market expansion deliver lasting benefits to patients in breast cancer."

Huzur Devletsah, Lilly Group Vice President and China General Manager, said: "For 150 years, Lilly has remained committed to putting health above all, advancing human health through scientific innovation and expanding access through collaboration. This agreement for Verzenios^® (abemaciclib) is an important step in strengthening patient access in China, combining Lilly's global R&D expertise with Innovent's commercialization capabilities in China. Looking ahead, Lilly will continue to advance its oncology efforts in China. Since the beginning of this year, we have secured approvals for one new medicine (with two indications) and two new additional indications for on market products in China, including Inluriyo^®, which has become the first and currently only approved precision therapy in China only targeting ESR1-mutated advanced breast cancer, accelerating the introduction of globally innovative therapies and addressing unmet medical needs."

About Innovent
Innovent is a leading biopharmaceutical company founded in 2011 with the mission to empower patients worldwide with affordable, high-quality biopharmaceuticals. The company discovers, develops, manufactures and commercializes innovative medicines that target some of the most intractable diseases. Its pioneering therapies treat cancer, cardiovascular and metabolic, autoimmune and eye diseases. Innovent has launched 19 products in the market. It has 1 asset in NMPA NDA review, 5 assets in Phase 3 or pivotal clinical trials and 14 more molecules in early clinical stage. Innovent partners with over 30 global healthcare companies, including Lilly, Takeda, Pfizer, Roche, Sanofi, Incyte, LG Chem and MD Anderson Cancer Center.

Guided by the motto, "Start with Integrity, Succeed through Action" Innovent maintains the highest standard of industry practices and works collaboratively to advance the biopharmaceutical industry so that first-rate pharmaceutical drugs can become widely accessible. For more information, visit www.innoventbio.com, or follow Innovent on Facebook and LinkedIn. 

Statement:
1) Innovent does not recommend the use of any unapproved drug (s)/indication (s).
2) Ramucirumab (Cyramza) and Selpercatinib (Retsevmo), Pirtobrutinib (Jaypirca) and abemaciclib (Verzenios) were developed by Eli Lilly and Company.
Disclaimer: Innovent does not recommend any off-label usage.

About Lilly 
Lilly is a medicine company turning science into healing to make life better for people around the world. We've been pioneering life-changing discoveries for 150 years, and today our medicines help tens of millions of people across the globe. Harnessing the power of biotechnology, chemistry and genetic medicine, our scientists are urgently advancing new discoveries to solve some of the world's most significant health challenges: redefining diabetes care; treating obesity and curtailing its most devastating long-term effects; advancing the fight against Alzheimer's disease; providing solutions to some of the most debilitating immune system disorders; and transforming the most difficult-to-treat cancers into manageable diseases. With each step toward a healthier world, we're motivated by one thing: making life better for millions more people. That includes delivering innovative clinical trials that reflect the diversity of our world and working to ensure our medicines are accessible and affordable.

Forward-Looking Statements of Innovent Biologics
This news release may contain certain forward-looking statements that are, by their nature, subject to significant risks and uncertainties. The words "anticipate", "believe", "estimate", "expect", "intend" and similar expressions, as they relate to Innovent, are intended to identify certain of such forward-looking statements. Innovent does not intend to update these forward-looking statements regularly.

These forward-looking statements are based on the existing beliefs, assumptions, expectations, estimates, projections and understandings of the management of Innovent with respect to future events at the time these statements are made. These statements are not a guarantee of future developments and are subject to risks, uncertainties and other factors, some of which are beyond Innovent's control and are difficult to predict. Consequently, actual results may differ materially from information contained in the forward-looking statements as a result of future changes or developments in our business, Innovent's competitive environment and political, economic, legal and social conditions.

LENOVO GROUP (00992.HK) is not only a long-term agreement customer of Micron Technology, Inc. (MU.US), but has also signed long-term supply agreements for storage products with Samsung and SK Hynix, Shanghai Securities News cited sources as saying.

LENOVO GROUP's China infrastructure business is radically raising its server business growth expectations, according to hearsay. The company previously set a server business target of RMB100 billion for FY2027/2028.

Based on currently executing orders, the confirmable revenue delivery scale from only two major customers next year has already approached RMB200 billion.
~

AASTOCKS Financial News
Website: www.aastocks.com

Samsung Electronics, SK Hynix and Micron Technology, Inc. (MU.US) are facing an antitrust lawsuit in the US. The three companies are accused of manipulating DRAM prices by deliberately reducing the supply of conventional DRAM under the pretext of expanding production of HBM, thereby driving up prices.

The plaintiffs include 14 US consumers and three small and medium-sized PC assembly and distribution companies. They alleged that the three companies have systematically restricted DRAM supply since 2022, giving rise to prices surging by about 700% over the past four years.

The plaintiffs contend that the defendants used inventory management as a justification to cut output, while in reality artificially creating shortages to raise prices.
~

AASTOCKS Financial News
Website: www.aastocks.com

倫敦2026年6月29日 /美通社/ -- 6月22日，「倫敦氣候行動周」期間，全球循環經濟倡導者艾倫•麥克阿瑟基金會與寧德時代、寶馬、雷諾、沃爾沃、谷歌、小米等企業宣佈共同發起「全球能源循環經濟聯盟」，並啟動《電池可循環設計指南》開發計劃。這是寧德時代在「全球能源循環計劃」（GECC）框架下，與基金會等合作夥伴共同推進的最新進展，標誌著電池循環經濟由願景邁入標準建設與商業實踐階段。

作為倫敦氣候行動周開幕旗艦活動「氣候創新論壇」的重要專題論壇之一，「循環經濟與零廢棄論壇」圍繞零碳轉型、循環經濟與氣候韌性等議題，匯聚來自全球的政府、企業、金融機構及社會組織代表，共同探討氣候行動與產業轉型路徑。寧德時代副總經理、董事會秘書蔣理，章魚能源投資總監兼聯合投資負責人王壚，谷歌全球氣候業務總監維魯沙利•高德，思愛普首席營銷官斯蒂芬•詹米森，國際能源署高級分析師肖邦•迪爾，以及艾倫•麥克阿瑟基金會關鍵礦產項目執行負責人翁文妤等出席了本次活動。

艾倫•麥克阿瑟基金會氣候項目負責人米蘭達•施尼特格認為，循環經濟是應對全球生產與消費環節45%的碳排放的關鍵路徑，也是氣候行動的重要槓桿。

「循環經濟不是電池產業增長的約束，而是形成更可持續、更可複製的經營模式。」寧德時代副總經理、董事會秘書蔣理表示，電池產業未來可以通過延長電池壽命、推動材料回收，全生命週期減碳，提升供應鏈韌性。

此次發起的「全球能源循環經濟聯盟」聚焦循環商業模式的規模化推廣，圍繞電池使用歷史、健康狀態、衰減數據、回收責任等關鍵維度建立統一評價依據，以幫助車企、物流企業、投資機構和政策制定者更準確評估電池資產價值和運營風險。艾倫•麥克阿瑟基金會將作為合作平台，推動產業鏈協作。

同時啟動的《電池可循環設計指南》將圍繞電池全生命週期，從易拆解、可診斷、可維修、可再製造和材料回收等環節建立設計原則與評價依據，覆蓋乘用車、商用車等不同交通應用場景，為整車企業、採購方、投資機構和監管部門提供行業參考。目前，相關工作已啟動，完整指南計劃於2027年發佈。

當前，產業亟需從單純擴大產能，轉向深耕全生命週期價值。2025年，寧德時代成為全球首家實現核心運營碳中和的新能源科技公司，旗下所有電池工廠成為「零碳工廠」，碳排放強度較2022年下降77%。自2023年以來，寧德時代已實施超過1000個節能項目，通過提升能效、推動工藝電氣化和擴大低碳電力使用，持續降低運營碳足跡。

製造端減碳只是第一步，電池價值鏈更大的減碳挑戰來自價值鏈。包括礦產開採與原材料加工在內的價值鏈碳排放是核心運營排放的五倍。目前，再生材料已帶動材料碳排放強度同比下降32%。控股子公司邦普2025年回收處理廢舊電池及材料21萬噸，鎳、鈷、錳回收率達99.6%，約80%的再生材料直接回用於寧德時代電池生產。

倫敦氣候週期間，寧德時代還與英國最大能源公司章魚能源宣佈將成立合資公司，共同建設歐洲重卡換電網絡。章魚能源創始人、首席執行官格雷格•傑克遜表示，換電、共享和智能調度等模式有助於提高電池利用效率，減少對新礦開採的依賴。

「全球能源循環計劃」是首個由中國企業發起的循環經濟公益項目，也是首個覆蓋新能源產業全產業鏈、政府與學術機構等多方力量的協作網絡，致力於推動電池循環經濟全面落地，助力新電池生產徹底擺脫對原生礦產資源的依賴。未來，各方將持續推動循環經濟路線圖在不同國家和地區開展試點，探索可複製、可推廣的循環解決方案。

LONDON, June 29, 2026 /PRNewswire/ -- On June 22, CATL and the Ellen MacArthur Foundation announced two new initiatives together with BMW, Renault, Volvo, Google, Xiaomi and other industry leaders and stakeholders, at the Climate Innovation Forum, the flagship event of London Climate Action Week 2026, through CATL's Global Energy Circularity Commitment (GECC), developed in strategic partnership with the Ellen MacArthur Foundation. The initiatives include circular battery design guidelines to embed circularity across the full battery lifecycle, and a business coalition to accelerate the policy, investment and commercial conditions needed to make circular business models the industry norm.

By 2040, the global battery recycling market alone is projected to exceed RMB 1.2 trillion, creating more than 10 million jobs, while the International Energy Agency projects demand for battery-critical minerals will increase fivefold over the same period. Meeting that demand sustainably will require not only greater recycling capacity, but common design standards and business models that keep materials in productive use for longer.

CATL became the first battery manufacturer to achieve carbon neutrality across its core operations in 2025, certified under ISO 14068-1, with full value-chain carbon neutrality targeted by 2035. Much of the remaining challenge lies in mining and raw material processing rather than manufacturing. Circularity will play a central role in meeting future demand without proportional increases in virgin material extraction. The initiatives announced aim to help build the common frameworks needed to accelerate that transition.

Earlier the same day, at Octopus Energy's Energy Tech Summit, CATL and Octopus Energy announced Europe's first battery-swapping joint venture, targeting 300,000 electric trucks and 30 hubs across Europe by 2035, with the first UK hubs scheduled to open in 2027. The partnership demonstrates the type of commercially viable circular business model the coalition aims to accelerate.

Miranda Schnitger, Climate Lead at the Ellen MacArthur Foundation: "Circular economy approaches were key to tackling the 45% of emissions that come from how we produce and consume."

Jiang Li, Vice President and Board Secretary, CATL: "Last year we set the direction: decouple battery growth from virgin material extraction. Today, the industry is beginning to build the common rules that will help deliver it. That is not only a climate opportunity, but an industrial one."

Greg Jackson, Founder and CEO, Octopus Energy Group: "By designing batteries to be swapped, optimised, shared and reused thousands of times, we can squeeze every drop of value out of the materials we already have, rather than digging up more. That's why our battery-swapping joint venture with CATL matters; we are taking the world's best hardware, combining it with smart energy tech to make it cheaper and more flexible, and building a completely self-sustaining transport network."

Initiative I: Circular Battery Design Guidelines

The circular battery design guidelines establish a common methodology for circular battery design across a range of mobility applications. As a founding partner, CATL brings practical experience from battery manufacturing, recycling and service operations to support their development. The methodology is intended to inform procurement standards, investor frameworks and future regulatory discussions, including the evolution of European battery policy.

Developed to address fragmentation across approaches to repair, second life and recycling, the guidelines provide a shared basis for comparing circular performance across the market. They aim to help buyers evaluate products, investors assess long-term value, and policymakers reference a consistent framework.

The Ellen MacArthur Foundation provides a neutral platform through which companies across the battery value chain can develop shared principles that no single organisation could establish alone. The working group is now underway, with publication planned for 2027.

Initiative II: Business Coalition for Circular Business Models

The coalition for circular business models is a policy and industry platform established to accelerate the adoption of circular business models across mobility and energy. With battery swapping already operating across more than 1,650 stations in 127 Chinese cities, the focus is shifting from demonstrating technical feasibility to creating the commercial, regulatory and financing conditions required for international scale.

CATL contributes practical experience through its battery-as-a-service and battery-swapping businesses, including the expanding Choco-Swap and QIJI networks, providing operational insights that can support wider deployment globally.

The coalition also seeks to establish common approaches for evaluating circular battery assets, including service history, degradation data and second-life value, providing investors, fleet operators and policymakers with greater confidence and reducing market uncertainty.

CATL Advances Circular Battery Systems

CATL continues to scale circularity across its operations. In 2025, Brunp Recycling processed 210,000 tonnes of end-of-life batteries, recovering 99.6% of nickel, cobalt and manganese, with 80% of recovered materials returning directly into CATL's battery production.

Rather than treating recycling as the end of a product's life, CATL integrates circularity into battery design, manufacturing, use and recovery as a connected system.

Furthermore, CATL is accelerating the commercialization of sodium-ion batteries, with plans to deliver its first sodium-ion energy storage systems to customers starting this September. This initiative expands the energy storage technology roadmap beyond lithium, cobalt, and nickel, enhancing material supply resilience and cost stability.

CHANGSHA, China, June 29, 2026 /PRNewswire/ -- At the Seventh Science and Technology Innovation Conference hosted by Zoomlion Heavy Industry Science & Technology Co., Ltd. ("Zoomlion"), the ZT82J straight-boom aerial work platform received an Outstanding Flagship Product Award. With a maximum working height of 82.3 meters, it is the world's tallest model in its category, addressing demand for aerial work equipment capable of operating above 80 meters and meeting the stringent safety demands of major infrastructure projects worldwide.

Behind this achievement is the persistent effort of product manager He Jipeng and his team at the Aerial Work Platform R&D Center, who drove the ZT82J from concept to mass production through design, testing, process implementation, and cross‑departmental coordination.

The core challenge from the outset was balancing two hard constraints, overall dimensions and total weight, while completing the structural layout. The R&D scope covered an ultra‑long, specially shaped lightweight boom, a box‑type turntable, and a high‑capacity chassis, aiming to reduce weight while significantly improving structural rigidity to ensure bending and torsional resistance under 82.3‑meter lifting conditions and suppress platform sway.

With no mature industry example and benchmark to follow, the team encountered bottlenecks including insufficient layout space, excessive weight, and inadequate rigidity. Weight reduction, overall dimensions and structural rigidity involved competing requirements, making it extremely difficult to find the optimal balance.

After over ten rounds of simulation, the team developed and refined a proprietary multi-edge boom cross-section and evaluated multiple telescoping configurations to optimize the overall structure. This ensured vertical and lateral stiffness while balancing weight-reduction targets with structural capacity within fixed limits.

Building on the lightweight boom, He Jipeng and the team integrated turntable and chassis optimization. Simulation identified weak stress points, precisely optimized plate cross‑sections, and reduced redundant steel while maintaining safety margins, achieving a lightweight upgrade, enhancing anti‑fatigue and anti‑overturning performance, and completing a structural breakthrough for ultra‑high working height equipment.

To support the project, Zoomlion assembled a task force of structural, hydraulic, and electronic control experts, backed by a simulation team and dedicated testing facilities, ensuring seamless coordination from design to production.

"This award recognizes our team's progress in developing ultra-high-reach aerial work platforms and demonstrates the capabilities of Zoomlion's high-end construction machinery," He Jipeng said. "It has also greatly boosted our confidence to continue pushing the boundaries of innovation and breaking through technical barriers."